In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.

Shares of Hologic Inc. HOLX shed 1.35% to $71.77 Tuesday, on what proved to be an all-around favorable trading session for ...

This was the stock's second consecutive day of gains.

Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close.

Hologic is down approximately 20% from recent highs and continues to grow organically and via a series of 'bolt-on' ...

Hologic Inc. has received a warning letter from the Food and Drug Administration regarding its BioZorb product line, even ...

Hologic Inc (HOLX) stock saw a modest uptick, ending the day at $71.02 which represents a slight increase of $0.32 or 0.45% from the prior close of $70.7. The stock opened at $70.45 and touched a low ...

Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Hologic in a research note issued on ...

The Hologic Women’s Health Index’s 2023 data found a decrease in testing for any cancer among women — a first in the survey’s ...

The U.S. Food and Drug Administration has sent a warning letter to Marlborough, Mass.-based medical technology company ...

Hologic CEO Steve MacMillan discusses the rise of cancer in younger women and the impact of artificial intelligence on the ...